company background image
25K logo

Karyopharm Therapeutics DB:25K Stock Report

Last Price

€1.36

Market Cap

€157.9m

7D

11.2%

1Y

-59.9%

Updated

28 Mar, 2024

Data

Company Financials +

Karyopharm Therapeutics Inc.

DB:25K Stock Report

Market Cap: €157.9m

25K Stock Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

25K fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Karyopharm Therapeutics Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Karyopharm Therapeutics
Historical stock prices
Current Share PriceUS$1.36
52 Week HighUS$4.16
52 Week LowUS$0.60
Beta0.0025
1 Month Change14.38%
3 Month Change66.30%
1 Year Change-59.92%
3 Year Change-85.01%
5 Year Change-72.85%
Change since IPO-95.55%

Recent News & Updates

Recent updates

Shareholder Returns

25KDE BiotechsDE Market
7D11.2%1.2%2.5%
1Y-59.9%34.7%7.0%

Return vs Industry: 25K underperformed the German Biotechs industry which returned 34.7% over the past year.

Return vs Market: 25K underperformed the German Market which returned 7% over the past year.

Price Volatility

Is 25K's price volatile compared to industry and market?
25K volatility
25K Average Weekly Movement21.4%
Biotechs Industry Average Movement5.7%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 25K's share price has been volatile over the past 3 months.

Volatility Over Time: 25K's weekly volatility has increased from 15% to 21% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008325Richard Paulsonhttps://www.karyopharm.com

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Karyopharm Therapeutics Inc. Fundamentals Summary

How do Karyopharm Therapeutics's earnings and revenue compare to its market cap?
25K fundamental statistics
Market cap€157.87m
Earnings (TTM)-€132.65m
Revenue (TTM)€135.37m

1.2x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
25K income statement (TTM)
RevenueUS$146.03m
Cost of RevenueUS$4.94m
Gross ProfitUS$141.09m
Other ExpensesUS$284.19m
Earnings-US$143.10m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.24
Gross Margin96.62%
Net Profit Margin-97.99%
Debt/Equity Ratio-222.7%

How did 25K perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.